LP-1 Cells
CAD$545.10*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | The LP-1 cell line is a well-established human multiple myeloma cell line derived from a patient with multiple myeloma. It is characterized by its t(4;14)(p16;q32) translocation, which results in the dysregulated expression of fibroblast growth factor receptor 3 (FGFR3). This genetic aberration is a hallmark of a subset of multiple myeloma cases and is associated with the pathogenesis and progression of the disease. LP-1 cells express a functional FGFR3, which, when activated, can engage the MAP kinase signaling pathway, promoting cell proliferation and survival. Notably, LP-1 carries a non-activating F384L mutation in the FGFR3 gene, distinguishing it from other myeloma cell lines with activating mutations of FGFR3. LP-1 cells are useful for studying the role of FGFR3 in multiple myeloma, particularly in the context of non-activating mutations. Research has shown that in multiple myeloma, FGFR3 mutations and other common oncogenic mutations, such as those in the Ras family, are typically mutually exclusive, suggesting that these mutations may contribute to tumorigenesis through similar or overlapping pathways. This makes LP-1 an invaluable model for exploring the molecular mechanisms underlying multiple myeloma and for testing targeted therapies aimed at the FGFR3 pathway. In addition to its relevance in FGFR3-related studies, LP-1 is also significant in research focused on the broader aspects of myeloma biology, including the role of cytokines like interleukin-6 (IL-6) in cell survival and proliferation. This cell line has been instrumental in studies that investigate the interactions between myeloma cells and their bone marrow microenvironment, as well as in the development of novel therapeutic strategies aimed at disrupting these interactions to control disease progression. |
|---|---|
| Organism | Human |
| Tissue | Peripheral blood |
| Disease | Multiple myeloma |
| Applications | Model to study the process of B lymphocyte maturation. |
| Synonyms | LP1 |
Characteristics
| Age | 56 years |
|---|---|
| Gender | Female |
| Morphology | Elongated single cells |
| Growth properties | Suspension |
Regulatory Data
| Citation | LP-1 (Cytion catalog number 300321) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_0012 |
Biomolecular Data
| Products | IgG lambda |
|---|---|
| Karyotype | Chromosome modal numer 73, distribution from 60 to 79 chromosomes |
Handling
| Culture Medium | IMDM, w: 4.5 g/L Glucose, w: 4 mM L-Glutamine, w: 25 mM HEPES, w: 1.0 mM Sodium pyruvate, w: 3.024 g/L NaHCO3 (Cytion article number 820800a) |
|---|---|
| Supplements | Supplement the medium with 20% heat inactivated FBS |
| Subculturing | It is recommended to seed the cells into a 24 well plate and cultivate for one week after thawing. Exchange the medium by dilution. Later on, the cells can be cultivated in regular cell culture flasks. Maintain culture between 0.5 to 1 x106 cells/ml. Incubate at 5% CO2, 37 degree Celsius. |
| Seeding density | 7 x 105 cells/well of a 24 to well to plate. |
| Post-Thaw Recovery | Viability may be low after thawing. |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 300321-240325 | Certificate of Analysis | 23. May. 2025 | 300321 |
| 300321-070125 | Certificate of Analysis | 23. May. 2025 | 300321 |